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Abstract
Introduction: Long-term follow-up after an acute coronary syndrome (ACS)
presents a crucial challenge due to the high residual cardiovascular risk and
the potential for major bleeding events. Although several treatment strategies are available, this article focuses on patients who have undergone percutaneous coronary intervention (PCI) for ACS, which is a frequent clinical
situation. This position paper aims to support physicians in daily practice to
improve the management of ACS patients.
Material and methods: A group of recognized international and French experts in the field provides an overview of current evidence-based recommendations – supplemented by expert opinion where such evidence is lacking – and a practical guide for the management of patients with ACS after
hospital discharge.
Results: The International Collaborative Group underlines the need of
a shared collaborative approach, and a care plan individualized to the patient’s risk profile for both ischaemia and bleeding. Each follow-up appointment should be viewed as an opportunity to optimize the personalized approach, to reduce adverse clinical outcomes and improve quality of life. As
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risks – both ischaemic and haemorrhagic – evolve over time, the risk–benefit balance should be assessed in
an ongoing dynamic process to ensure that patients are given the most suitable treatment at each time point.
Conclusions: This Expert Opinion aims to help clinicians with a practical guide underlying the proven strategies and the remaining gaps of evidence to optimize the management of coronary patients.
Key words: acute coronary syndrome, follow-up, expert position paper, long-term care, percutaneous
coronary intervention.

Introduction
During the last decades, a dramatic decline has
been observed in patients with acute myocardial infarction (AMI) in hospitalizations, case-fatality rates and long-term survival and events.
This reflects the widespread application of evidence-based treatment such as reperfusion therapy during the acute stage as well as immediate
and long-term implementation of preventive strategies. However, the recent years of the pandemic
have reversed these positive trends and pose new
challenges to healthcare providers and physicians.
Guidelines for the treatment of acute coronary
syndromes (ACS), either ST-segment elevation
myocardial infarction (STEMI) [1] or non-ST-segment elevation myocardial infarction (NSTEMI) [2],
and cardiovascular prevention [3] such as those
of the European Society of Cardiology (endorsed
by the French Society of Cardiology) allow broad
access to the different available evidence-based
strategies either during hospitalization or after
discharge for secondary prevention. However,
several registries have demonstrated that, on one
hand, the application of these guidelines, especially for further follow-up after discharge, is often
not optimal and that, on the other hand, a high
residual risk of major events persists, even for
“apparently stable” patients in secondary prevention. One explanation could be a lack of adequate
communication between cardiologists and other
health professionals either directly involved in
ambulatory cardiovascular care (including general
practitioners, pharmacists, nurses and physiotherapists) or susceptible to delivering care which can
interfere with the ongoing cardiovascular treatment (surgeons, anaesthesiologists, dental surgeons). Another important reason is that there are
large country-to-country differences in drug availability (including reimbursement criteria for new
drugs) and physicians’ and patients’ knowledge.
Thus, transition of care (TOC) from the hospital to an ambulatory setting and further follow-up
appears to be a crucial period. Therefore, after an
ACS, optimization of the management of coronary
outpatients (including considering of so-called
coordination care), according to evidence-based
guidelines, could benefit from a better consideration of real-life experience. The main goal of this
position paper is to provide to French physicians
(non-hospital cardiologists and general practi-
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tioners), and indirectly to other health professionals, convenient guidance for better application of
EBM such as presented in reference guidelines for
the management of patients with ACS after discharge from hospital.

Material and methods
A group of French and recognized international
experts involved in the initial and follow-up care of
patients with ACS was invited by the Collège National des Cardiologues Français and the Collège
National des Cardiologues des Hôpitaux to form
a working group (Transition Care group). The first
objective of the experts was, according to registries of clinical practice and to their own experience, to identify which points of the most recent
guidelines on coronary patients [1–3] were most
often missed. The second objective was to propose actions and tools aimed at providing a practical guide for optimisation of long-term follow-up
of these patients. Even though several treatment
strategies are available, this article is focused on
patients who have undergone percutaneous coronary intervention (PCI).
Our findings are arranged by topic, beginning
when the patient is discharged from hospital, and
covering the first 12–24 months, which are the
most crucial to prevent recurrent events.

Results
Discharge letter and instructions
for patients
Patient follow-up after ACS is crucial to avoid
a premature recurrent event and should involve
a well-planned transition of care from the hospital to the patient’s cardiologist, general practitioner (GP) and any other associated healthcare
providers. This process should involve a personalised and evolving approach to optimize clinical
outcomes. An early ambulation (day 1) is usual for
most STEMI or NSTEMI patients without residual
ischaemic or heart failure clinical signs, and with
no arrhythmic or mechanical complications. This
mobilisation is facilitated by the implementation
of radial access for PCI, and the hospital should
provide a discharge letter following the standardized discharge letter after hospital stay [4].
The list of the information to include in the discharge letter is detailed in Table I.
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Table I. Content of the hospital discharge letter
Hospital name/address
Name of cardiologist

Address

Name of GP

Address

Patient name
Age

Date of birth

Sex
Home address
Date of discharge
Discharge diagnosis
Clinical information
Comorbidities and cardiovascular risk factors
Peak (hypersensitive or normal) troponin level during hospitalization
LVEF at discharge
Single vessel/multivessel disease
PCI information
Technique (e.g. cc, iode-DLP)
Images (DICOM-compatible DVD)
Results
Complications during PCI
Number of arteries treated
Number of stents implanted
Type of stents implanted: BMS, DES or BVS
Patient provided with educational material (cardiovascular disease
prevention, medication, recognizing symptoms, actions to take in the
event of an adverse reaction or symptoms of ischaemia)?

Yes/No

Discharge medications
DAPT

Drug name/dose

Recommended minimum
duration

< 1 year ………
≥ 1 year ………
Other ………

Reasons for duration (bleeding and ischaemic risks)

Ischaemic risks

Bleeding risks

OAC

Indication and drug name/dose

β-Blockers

Drug name/dose

Lipid-lowering therapy

Drug name/dose

Treatment goal:

ACE inhibitors or ARBs

Drug name/dose

Treatment goal:

GP

Every 3 months

Cardiologist

1, 6, 12 months, annually
thereafter (in the absence
of a recurrence)

Biological tests (ALT/AST) for safety of statin therapy
(8 weeks after instauration according
to HAS guidelines of dyslipidaemia)
Recommended follow-up times

ACE – angiotensin-converting enzyme, ALT – alanine aminotransferase, ARB – angiotensin receptor blocker, AST – aspartame
aminotransferase, BMS – bare-metal stent, BVS – bioresorbable vascular scaffold, DAPT – dual antiplatelet therapy, DES – drug-eluting
stent, GP – general practitioner, HAS – Haute Autorité de Santé, LVEF – left ventricular ejection fraction, OAC – oral anticoagulant,
PCI – percutaneous coronary intervention.
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Table II. Checklist (cardiologist or general practitioner) for follow-up consultations after acute coronary syndrome
Category

Goal

Recommendation(s) (if not at goal)

Tobacco smoking

Smoking cessation

• Smoking cessation counselling
(possibly nurse led)
• Nicotine replacement
• Bupropion and antidepressants may
be useful

Heart rate

Range 50–70 bpm

Increase β-blocker dosage

Left ventricular function

N/A

Body weight

Body mass index < 25 kg/m

Diet

Healthy well-balanced diet

Waist circumference

< 102 cm in men and < 88 cm in women

Sedentary lifestyle

Moderate to vigorous exercise
≥ 150 min/week

Encouragement of physical activity, with
exercise-based rehabilitation

Dyslipidaemia

• < 1.4 mmol/l (55 mg/dl) in very high-risk
patients, with a reduction ≥ 50% from
baseline
• Non-fasting blood samples can be used
but may underestimate risk in patients
with diabetes, and should not be used for
patients with severe dyslipidaemias

• High-dose statin doses
• Consider addition of other lipidlowering therapy
• For some patients consider upfront
combination therapy

Glycated haemoglobin

• Glycaemic control: < 7% (53 mmol/mol)
• Less stringent glucose control should be
considered in patients with more advanced
cardiovascular disease, older age, longer
diabetes duration and more comorbidities

Glucose-lowering therapy

Blood pressure

Strict blood-pressure control:
< 140/90 mm Hg [81]

Antihypertensives

Adherence to secondary
prevention medications

Adherence to all indicated medications

• Reinforcement of benefits
of secondary prevention medication
• Referral to cardiac rehabilitation

Clinical symptoms

Awareness of clinical signs of acute disorder

Careful examination at each visit

Depression

Evaluation (Beck scale) and treatment
if necessary

Careful examination at each visit

N/A

Additionally, patients and their family members
should be involved with discharge instructions
about recognizing acute cardiac symptoms as well
as the clinical signs of transient ischaemic attack
or stroke. They also should be provided with clear
instructions detailing lifestyle changes and their
medication at discharge, including possible side
effects and the risks associated with premature
discontinuation of treatments [4, 5]. They must be
aware that any bleeding does not systematically
imply treatment cessation and they must understand what nuisance bleeding is. The letter should
be given to the patient before discharge, even
during weekends or on public holidays.

Management of ACS after discharge from
hospital
An effective and coordinated evidence-based
outpatient care plan – encompassing scheduled
follow-up, appropriate personalised dietary and
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Advice on diet, nutrition, and weight
control

2

physical exercise recommendations, information
on smoking and alcohol cessation, and adherence
to treatments for secondary prevention [6] – is crucial for improving outcomes after an ACS. Timely
follow-up is a key component of a transitional care
model that reduces hospital readmission rates [7].

Transition care: the cardiologist and the GP
Both cardiologists and GPs play important roles
in the long-term follow-up of patients, with regular reassessment of ischaemic and bleeding risks,
adherence to treatment, management of adverse
reactions, comorbidities and risk-factor management. At every stage of the follow-up, the shared
medical decision with the patient and family
members is key to reduce the residual risk.
The medical strategy will depend upon the
patient’s stage of illness and life expectancy, the
presence of comorbidities (e.g. chronic kidney
disease, atrial fibrillation, diabetes mellitus or im-
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Discharged on secondary
prevention medications and cardiac
rehabilitation

1–2 month
follow-up

6 month
follow-up

12-month
follow-up

Annual
follow-up

Cardiologist

Cardiologist

Cardiologist

Cardiologist

GP

GP

GP

GP

GP

GP

GP

GP

Routine clinical evaluation (by GP/cardiologist)
• Smoking cessation
• LDL-C goals < 55 mg/dl (1.4 mmol/l) and > 50% decrease from baseline
• TG < 150 mg/dl
• Glycated haemoglobin below 7% or 6.5% for young patients
• GLP1RA or SGLT2i for T2D patients
• Home BP < 135/85 mm Hg (or < 140/90 mm Hg in clinical visit)
• Clinical cardiac symptoms
• Depression symptoms
• Patient education
• Adherence and tolerance
• Food advices
• Physical activity advices (goal > 150 min/week)
• Weight control (BMI < 25 kg/m2)
GP – general practitioner, HbA1c – haemoglobin A1c, TG – triglycerides, GLP1RA – GLP1
receptor agonists, SGLT2i – SGLT2 inhibitors, BP – blood pressure, BMI – body mass index.

Figure 1. Recommended follow-up after discharge for patients with ACS. Adapted from the French Haute Autorité
de Santé recommendations [5]

paired cognitive functions), and the regional organization. The cardiologist plays a key role in the
development of a comprehensive global risk-management strategy, the definition of treatment
goals, the control of cardiovascular risk factors
and the management of clinical events (Table II).
The role of the GP is obviously crucial due to
the intimate knowledge and understanding of the
patient. GPs can deal with early adverse reactions
and be responsible for signalling the early signs
of disease progression. GPs and cardiologists, in
a strict collaborative fashion, are responsible for
treatment adjustments and the management of
major serious events. There is a great need for improved collaboration and communication, routine
use of local networks, and shared patient files.
Telemedicine may improve patient management.

Follow-up schedule
According to the AFSSAP (French National
Health Agency) regular follow-up after ACS is recommended by both the cardiologist and the GP
[8]. Based on the guidelines, in order to be on target as early as possible, the first meeting should
be 4–6 weeks and the second one in another 4–6

weeks to rapidly reach the LDL-C goals [8]. This
approach should be complemented by regular
follow-up visits to the GP, ideally on a 3-monthly basis, especially in the presence of associated
non-cardiac illness. The timing of consultations
and actions required are illustrated in Figure 1.

Follow-up during the 1–6-month post-ACS
period
During early follow-up consultations, the cardiologist and/or GP and patient can discuss activities such as return to driving and/or work, sexual
and physical activities, cardiac rehabilitation and
other quality of life measures.
The early consultation provides an ideal time to
check for – and manage – any adverse reactions
(e.g. myalgia, nuisance bleeding or tiredness) that
can reduce adherence to treatment [9, 10].
This first contact also gives the opportunity to
reinforce the importance of continuing secondary
prevention measures, optimizing risk factor control and therapeutic goal achievements, adopting a healthy lifestyle, and appropriate education
about the disease. Among patients with pre-discharge left ventricular ejection fraction (LVEF)
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Table III. Tests to be performed during follow-up after percutaneous coronary intervention for an acute coronary
syndrome
Test

To evaluate

Performed
routinely?

When should the test
be performed?

Left ventricular function

No

6–8 weeks after discharge in
case of impaired LVEF or new
signs; during the long-term
follow-up in case of new signs

Holter monitoring

Arrhythmias identification

No

In the presence of symptoms
or with abnormal
electrocardiogram

Exercise stress test

Functional cardiac capacity/
residual ischaemia

No

During cardiac rehabilitation,
before a sports certificate

Stress echocardiography
or myocardial scintigraphy

Ischaemic risk

No

In the presence of symptoms
or incomplete revascularization

Coronary computed
tomography angiography

Coronary anatomy

No

In the presence of symptoms
or residual ischaemia

Selective coronary
angiography

Coronary anatomy

No

In the presence of symptoms
or residual ischaemia

Lower extremity artery disease
screening

Yes

Every year

Carotid stenosis screening

No

ONLY if SYMPTOMS or carotid
murmur

Abdominal aortic aneurysm
screening

No

Age > 50 years

Lower extremity artery disease

No

Only if ankle-brachial index
< 0.9 or absent pulses or in
presence of symptoms

Echocardiogram

Ankle-brachial index
Duplex ultrasound

LVEF – left ventricular ejection fraction.

≤ 40%, repeat echocardiography 6–12 weeks after
revascularization and optimal medical therapy is
recommended to assess the potential need for an
implantable cardioverter defibrillator (ICD) [11].

Follow-up during the 6–12-month post-ACS
period and beyond
By 6 and 12 months, the patient’s ischaemic
and haemorrhagic risks should be re-assessed
to determine the duration of DAPT [12, 13]. Follow-up activities should be consistent with those
outlined during the post-discharge consultations.
In addition, as in early consultations, any contact
with the patient is an opportunity to reinforce the
importance of continuing secondary prevention
measures and optimizing risk factor control. If
the goals are not achieved, emphasis should be
placed on optimizing the treatment and starting
the combination therapy, so the patients achieve
the goals as early as possible [6].
Ischaemic tests (e.g. stress imaging, exercise testing) are recommended if recurrent symptoms occur
(Table III). The systematic use of ischaemic tests remains debated, requiring a dedicated randomized
controlled trial (RCT). In case of doubts about the
presented symptoms, the diagnosis of microvascular coronary disease should be considered.
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Use of recreational drugs (e.g. cannabis, cocaine) that promote coronary thrombus formation
and vasospastic angina [14] is widespread among
young patients and warrants identification to ensure appropriate management. The psychosocial
profile should also be assessed to prevent burnout and depression [5].
Global atherosclerotic disease investigation
and imaging should not be systematically performed according to current guidelines, even if
it may be discussed, as the ankle-brachial index
test is rapid, cheap, and provides additional information about the cardiovascular (CV) risk. The
current strategy is to perform additional examinations following a clear rationale (Table III).

Treatment strategy
The European Society of Cardiology (ESC) 2017
STEMI guidelines recommended a ‘BASI’ approach
to secondary prevention therapy after an acute
myocardial infarction (MI), in which all patients
should receive a b-blocker, an antiplatelet, a statin, and an angiotensin-converting enzyme (ACE)
inhibitor or angiotensin receptor blocker (ARB)
[15]. The recommendations on secondary prevention therapies have since evolved, and the BASI
approach is no longer applicable to all patients
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Table IV. Secondary prevention therapies in acute coronary syndrome patients [1, 2, 16, 17]
Drug class

Treatment

Class and level

Antiplatelet

Indefinite treatment with low-dose aspirin (75–100 mg/day), in the absence
of contraindications

IA

Clopidogrel in patients intolerant of aspirin

IB

DAPT (aspirin + P2Y12 inhibitor (see below)), in the absence
of contraindications, in patients treated with PCI

IA

DAPT for up to 12 months, unless there are contraindications:

IC

P2Y12 inhibitor in addition to aspirin for > 1 year after assessment
of the patient’s ischaemic and bleeding risks

IIb

DAPT for up to 1 year in patients without a stent

IIa

In patients with a clear indication, OAC (VKA or NOAC) in addition
to antiplatelet therapy NOAC

IC

OAC

DOAC should be preferred. Duration of DAPT should be minimized (7 days)
to reduce bleeding risk

IC

SGLT2
inhibitors

Patients with heart failure with reduced ejection fraction (HFrEF), diabetes,
chronic kidney disease (CKD)

ACE inhibitor
or ARB

Vericiguat
Lipidlowering
therapy (LLT)

Ticagrelor
(90 mg bid)

Prasugrel
(10 mg (5 mg
in patients
< 60 kg))
Clopidogrel
(75 mg)

An ARB as an alternative to ACE inhibitor in patients with heart failure
or LV systolic dysfunction, particularly for patients intolerant
of ACE inhibitors

IB

All patients without contraindications

IIaB

Patients with heart failure or LV dysfunction (LVEF ≤ 40%)

IA

Initiation of high-dose statins in patients without contraindications or history
of intolerance, regardless of initial cholesterol values

IA

Addition of further lipid-lowering therapies to statin therapy if the LDL-C
target is not achieved (< 1.4 mmol/l (55 mg/dl)) with the highest tolerated
dose of a statin

IIaA

If the LDL-C target is not achieved with the highest tolerable dose of a statin
and ezetimibe, a PCSK9 inhibitor is recommended on top of lipid-lowering
therapy; or alone or in combination with ezetimibe in statin-intolerant
patients

IA

In post-ACS patients with (1) extreme cardiovascular risk, (2) familial
hypercholesterolaemia, or (3) baseline LDL-C concentration that prevents
achievement of the treatment goal with statin therapy, upfront combination
therapy with ezetimibe may be considered.

IIbC

NSTEMI-ACS [2] (class and level of recommendation)

STEMI [1] (class
and level of
recommendation)

Moderate to high risk cardiovascular risk patients without
contraindications,a regardless of initial treatment strategy and including those
pre-treated with clopidogrel (IB)

Ticagrelor
preferred
over clopidogrel
(IA)

Patients planned for PCI (IB) without contraindicationsb
Not recommended for patients with unknown coronary anatomy (IIIB)

Prasugrel preferred
over clopidogrel
(IA)

Patients who cannot receive ticagrelor or prasugrel or who require OAC (IB)

Preferably when
prasugrel and
ticagrelor are not
available or are
contraindicated (IC)

ACE – angiotensin converting enzyme, ACS – acute coronary syndrome, ARB – angiotensin receptor blocker, bid – bis in die (twice daily),
DAPT – dual antiplatelet therapy, LDL-C – low-density lipoprotein cholesterol, LV – left ventricular, LVEF – left ventricular ejection fraction,
NOAC – non-vitamin K antagonist oral anticoagulant, NSTEMI – non-ST-segment elevation myocardial infarction, OAC – oral anticoagulant,
PCI – percutaneous coronary intervention, PCSK9 – proprotein convertase subtilisin/kexin type 9, STEMI – ST-segment elevation myocardial
infarction, VKA – vitamin K antagonist. aPrevious intracranial haemorrhage or ongoing bleeds. bPrevious intracranial haemorrhage,
ischaemic stroke or transient ischaemic attack or ongoing bleeds; prasugrel is generally not recommended for patients ≥ 75 years of age
or with a bodyweight < 60 kg.
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with acute MI, especially for β-blockers and ACE
inhibitors/ARBs. It refers also to antihypertensive
therapy and lipid-lowering therapy, when upfront
combination therapy is recommended for those
patients who are at the highest cardiovascular
risk (including those with so-called extremely high
cardiovascular risk) [16–18]. The routine secondary
prevention therapies for ischaemic heart disease
are detailed in Table IV [1, 2, 16].

Antithrombotic treatment
Ischaemic and haemorrhagic risk assessment
should be a dynamic process, as these evolve
separately over time. This is the main reason why
short- and long-term follow-up is necessary. We
also advocate an adaptive approach, in response
to the occurrence of an ischaemic or bleeding
event, which may warrant a transient interruption.

Dual antiplatelet therapy
ESC guidelines 2017 (STEMI) and 2020 (NSTEMI)
recommend that ACS patients should receive DAPT
(comprising aspirin and a P2Y12 inhibitor) [2]. Currently, a 12-month DAPT therapy is considered as
the default strategy in accordance with the results
of several major trials [2]. As “one size doesn’t fit
all”, the duration of DAPT should be individualized
according to the benefit–risk ratio and adapted
to events. Three oral P2Y12 inhibitors are available
for the prevention of ischaemic events (Table IV):
ticagrelor and clopidogrel are indicated for all
types of ACS, whereas prasugrel is indicated for
clopidogrel-naïve ACS patients scheduled for
PCI and without previous history of stroke [1, 2].
Supplementary Table SI provide some pharmacological properties of these drugs. Prasugrel and
ticagrelor are more effective than clopidogrel for
reducing major ischaemic cardiovascular events,
but are associated with an increased risk of bleeding (Supplementary Table SII) [19–21] and are contraindicated in some groups [21–23]. Platelet function monitoring to adapt the dose or type of P2Y12
inhibitors should not be used in ACS patients [24].
The preferred choice of prasugrel in PCI patients
with NSTEMI is a class IIb based on the ISAR REACT 5 results.

Long-term DAPT: 12 months and beyond
Numerous RCTs have evaluated the effect of
longer- versus shorter-term DAPT in patients with
ACS (see Supplementary Table SIII [25–41]). The
PEGASUS-TIMI 54 study [37] supports longer-term
use of DAPT beyond 12 months, with significant
reductions in MI and stroke compared with aspirin
alone, despite an increase in bleeding. The DAPT
study [33], which compared 30 versus 12 months
of DAPT (clopidogrel or prasugrel), supports lon-

846

ger-term use of DAPT beyond 12 months to reduce
the risk of ischaemic events and stent thrombosis,
but with an increased risk of bleeding and an increase of non-cardiovascular death and total mortality which has not been fully explained [33, 42].
The remaining studies detailed in Supplementary
Table III, which were overall underpowered, reported no significant improvement for longer- versus
shorter-term DAPT. The MASTER DAPT study advocates a 1 month duration in patients with high
bleeding risk (HBR) but included a majority of
chronic coronary patients.
According to various guidelines, extended DAPT
beyond 1 year with ticagrelor should be considered for a minority of patients at high ischaemic
risk without a major bleeding event or increased
bleeding risk [2, 42].
At 1-year follow-up, the DAPT score [43] may be
helpful to guide the decision to continue DAPT beyond 12 months, but should complement, not replace, the clinician’s judgment. Factors to consider
when identifying the optimum duration of DAPT
are illustrated in Figure 2. The duration should be
tailored to each patient’s ischaemic and haemorrhagic risk profile [44, 45], including the occurrence of events in the preceding period as well
as their angiographic and clinical characteristics.
Uncontrolled risk factors are obviously important
to consider when estimating the risk of recurrent
events [46]. The levels of ischaemic and haemorrhagic risk evolve over time, and thus require regular assessment of the benefit–risk balance.
As an alternative, the recent COMPASS trial
has suggested that, in patients who require an
aggressive long-term antithrombotic regimen, an
association of low-dose aspirin and low-dose rivaroxaban may be considered [47].

Early discontinuation of DAPT after PCI
for ACS
Discontinuation of the P2Y12 inhibitor after 6 or
even 3 months may be justifiable in patients at
high risk of bleeding [42]. The PRECISE-DAPT score
[48] can be used to estimate haemorrhagic risk
and informed discharge letter recommendations
on treatment duration (Figure 2) [2, 7]. Patients reporting recurrent/persistent episodes of nuisance
bleeding (but with low ischaemic risk) and those
who require surgical intervention may be considered for single antiplatelet therapy rather than
continuing DAPT (expert opinion). A recent study
from Belgium reported that the most common
reasons for stopping antiplatelet treatment before
11 months (among 295 ACS patients) were surgery
(25%) and high bleeding risk (19%) [25].
In post-ACS patients who require surgical intervention, the risk of surgery-related bleeding must
be balanced against that of recurrent ischaemic
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Criteria for DAPT < or ≥ 1 year

Short duration of DAPT

•
•
•
•
•
•
•
•
•

Criteria for a DAPT duration < 6 months
History of major bleeding
HBR (high bleeding risk)
Persistent nuisance bleeding
Oral anticoagulant therapy
Anaemia
PRECISE-DAPT* score ≥ 25
Planned major surgery
Age > 85 years
End stage renal disease

Extended duration of DAPT

•
•
•
•
•
•
•
•

Criteria for a DAPT duration ≥ 1 year
Low bleeding risk
High ischaemic risk
Recurrent ACS
Multiple vascular bed disease (PAD, carotid stenosis)
Anatomical factors (left main artery, multivessel coronary
disease, bifurcation)
Procedural factors (multiple, long or small stents, complex
procedure, incomplete revascularisation)
Diabetes mellitus
Uncontrolled ischemic risks factors (e.g. smoking, LDL-C,
diabetes)
DAPT score ≥ 2
PRECISE-DAPT* score < 25

Figure 2. Factors to consider when deciding on the optimal duration of dual antiplatelet therapy in patients with
ACS. *For the PRECISE-DAPT score [17, 48]
ACS – acute coronary syndrome, DAPT – dual antiplatelet therapy, LDL-C – low-density lipoprotein cholesterol, PRECISE-DAPT – PREdicting
bleeding Complications In patients undergoing Stent implantation and subsEquent Dual AntiPlatelet Therapy.

events related to interruption of antithrombotic
therapy. This assessment should involve the type
of surgery, patient’s ischaemic risk, time since the
index event and PCI, and the risk of stent thrombosis. DAPT can then be discontinued or changed
to a DAPT regimen with a lower bleeding risk (e.g.
switch from aspirin plus prasugrel/ticagrelor to aspirin plus clopidogrel [49]). In patients who have
had their DAPT regimen interrupted for surgery,
this should be restarted after a period depending on surgery type and post-operative course. If
aspirin is stopped, it is recommended to restart
24 h after low-bleeding-risk procedures or 48–72 h
after higher-bleeding-risk procedures. While the
maximal antiplatelet effect occurs within minutes
after taking aspirin, the maximal antiplatelet effect of clopidogrel may not be reached until after
7 days of daily administration of a standard dose
(75 mg/day) [50]. The antiplatelet effects are faster and more predictable with ticagrelor and prasugrel.
After stent implantation, elective surgery requiring discontinuation of P2Y12 inhibitors can
be considered after 1 month, irrespective of the
stent type, if aspirin can be maintained throughout the perioperative period (Class IIa; level B). In
patients with recent MI, non-urgent surgery may
be delayed until ≥ 6 months after the index MI
event (IIb C). For patients in whom surgery cannot
be delayed, DAPT should be continued in those

considered to be at low bleeding risk and high
ischaemic risk, whereas aspirin alone should be
continued in patients at low ischaemic risk and
high bleeding risk.
For non-cardiac surgery that cannot be delayed,
a minimum of 1 month of DAPT is recommended [2].

New option of antiplatelet strategy after
PCI for ACS patients
The TWILIGHT study enrolled 9,006 patients
between July 2015 and December 2017 [51]. The
patients were treated with PCI for ACS (64.8% of
the population) or planned PCI. Trial inclusion criteria required the presence of at least one clinical and one angiographic feature associated with
a high risk of ischaemic and/or bleeding events.
After 3 months of DAPT, event-free patients
were randomly assigned to aspirin or placebo
with continuation of ticagrelor for an additional 12 months. 7,119 patients were randomized in
11 countries (median age: 65.2 years old, 36.8%
with diabetes mellitus, 23.8% females.). The primary endpoint was the rate of Bleeding Academic
Research Consortium (BARC) 2, 3, or 5 bleeding.
The secondary endpoint was all-cause death,
myocardial infarction, or stroke. The strategy with
ticagrelor plus placebo was associated with an
incidence of major bleeding of 4.0% for patients
with 3 months DAPT versus 7.1% among patients
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who received ticagrelor plus aspirin for 12 months
(hazard ratio (HR) = 0.56; 95% confidence interval
(CI): 0.45 to 0.68; p < 0.001). Similar findings were
reported for BARC 3–5 bleeding (1.0% vs. 2.0%;
HR = 0.49; 95% CI: 0.33 to 0.74). Rates of all-cause
death, myocardial infarction, or stroke were 3.9%
for both groups (HR = 0.99; 95% CI: 0.78 to 1.25;
pnoninferiority < 0.001). The rates of all-cause death
(1.0% vs. 1.3%), myocardial infarction (2.7% vs.
2.7%), and definite or probable stent thrombosis (0.4% vs. 0.6%) were also similar between
groups. No heterogeneity was observed irrespective of the ischaemic risk of the prespecified subgroups. The TWILIGHT study demonstrated that
a shorter duration of DAPT (3 months) followed
by single antiplatelet therapy (SAPT) with ticagrelor bid, compared to the recommended DAPT of
12 months’ duration, provides a 44% relative risk
reduction of BARC 3–5 bleeding, with a similar rate
of ischaemic events, and with a consistent effect
in all ischaemic risk profiles. These findings will
be considered in the next guidelines to optimize
the antiplatelet strategy, and a DAPT of 3 months
followed by ticagrelor bid in monotherapy seems
a valid option by reducing bleeding risk without
increasing ischaemic risk.

Triple antithrombotic therapy
Current guidelines for the management of patients on long-term oral anticoagulant (OAC) therapy undergoing coronary stenting are based on
expert consensus [2, 52–54]. This frequent clinical
situation of complex patients requires a collaborative decision involving the patient. The recent
ESC guidelines suggest [2]: a limited period of triple antithrombotic therapy (OAC plus aspirin and
clopidogrel) for as short a time as possible (7 days)
irrespective of the type of stent used (IIa B); triple
therapy for > 1 month and up to 6 months should
be considered in high ischaemic risk patients due
to ACS or other anatomical/procedural characteristics that outweigh the bleeding risk (IIa B);
dual therapy with clopidogrel and OAC should be
considered as an alternative to 1 month of triple
therapy in patients in whom the bleeding risk outweighs the ischaemic risk (IIa A); after 12 months,
discontinuation of all antiplatelet therapy should
be considered (pursue OAC alone) (IIa B) [55]. Use
of a direct OAC is preferable to a vitamin K antagonist (warfarin only). Prasugrel and ticagrelor
should not be used in the triple combination due
to excess risk of bleeding. An antiplatelet agent
may be prolonged for high-risk thrombotic situations (left main and/or multiple stenting, recurrent ischaemic events, or previous stent thrombosis). The ESC STEMI guidelines advised that OAC
should be considered for up to 6 months once
the thrombus is identified, guided by repeated
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echocardiography and with continuous evaluation of bleeding risk and the need for concomitant antiplatelet therapy. The optimal duration of
OAC in these patients remains unclear; therefore
decisions regarding the OAC duration should be
individualised.

Lipid-lowering therapy
Based on the guidelines, all ACS patients without contraindications, regardless of their low-density lipoprotein cholesterol (LDL-C) level, should
be started on high-dose statin (atorvastatin
40–80 mg or rosuvastatin 20–40 mg) therapy
during hospitalization. For US guidelines, the
LDL-C target is below 70 mg/dl, whereas ESC
guidelines consider a lower level below 55 mg/dl,
due to the proven benefits reported by recent
RCTs, with a reduction of ≥ 50% from baseline
(if > 1.8 mmol/l) [56–62]. It needs to be emphasized that ESC/EAS 2019 guidelines [56] also introduced the extremely high-risk category, for those
with 2 vascular events in the last 2 years, which
was next extended in different national and international recommendations, for which the targeted
level of LDL-C should be < 40 mg/dl (1 mmol/l). It
is important as secondary prevention patients at
very high risk are a very heterogenous group [63].
Dose adjustment and the addition of ezetimibe
on top of the maximally tolerated statin dose are
necessary in patients whose LDL-C value remains
above the goal [56–58]. The protein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors (evolocumab and alirocumab) should be considered
(based on the reimbursement criteria) if patients
are not at LDL-C goal (above 70 mg/dl) with the lipid-lowering combination statin and ezetimibe. Inclisiran was approved by the European Medicines
Agency (EMA) in December 2020 twice a year
(3 times a year in the first year of the therapy) and
will be a great complement to the PCSK9 inhibitor
therapy. For patients at extremely high cardiovascular disease (CVD) risk and those with very high
baseline LDL-C levels that do not allow them to
be on goal with statin monotherapy (assuming
about 50% LDL-C reduction) upfront lipid-lowering
combination therapy with statins and ezetimibe
should be considered [14, 18].
Based on the most recent data, the worldwide
prevalence of statin intolerance is 9.1% [59–64].
Patients who report symptoms of statin intolerance should always be diagnosed based on the
approved definitions [9] assessed using the statin associated muscle symptoms clinical index
(SAMS-CI) [65]. Recent data suggest that nocebo
effects might be responsible for even 50–70% of
the cases [66]. The ESC/European Atherosclerosis
Society (EAS) have published joint recommendations for the management of myalgia with statins
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using a clinical algorithm [9, 64]. Bempedoic acid,
besides innovative drugs associated with PCSK9
inhibition, alone or in fixed combination with ezetimibe, is a very effective option in patients with
confirmed statin intolerance [9, 67].

Other secondary prevention medications
The systematic use of β-blockers and ACE inhibitors/ARBs in all ACS patients is no longer recommended [2], and physicians should consider
stopping these treatments in patients without
clear indications. β-Blockers should not be administered in patients with symptoms possibly related
to coronary vasospasm or cocaine use [2].
ESC guidelines state that ACE inhibitors are
recommended (IA) in patients with heart failure,
left ventricular systolic dysfunction, diabetes mellitus or renal failure [1, 2]. An ARB can be used as
an alternative in patients with heart failure and/
or left ventricular systolic dysfunction, and in patients who are intolerant of ACE inhibitors. Mineralocorticoid receptor antagonists (MRA) are also
a therapeutic option in patients with left ventricular dysfunction, symptomatic despite optimal
medical therapy.
Long-term treatment with oral β-blockers is recommended, in the absence of contraindications,
for all patients with STEMI [1] and for non-ST-elevation ACS patients with LVEF ≤ 40% [2]. Their
long-term benefit in patients with preserved ejection fraction or LVEF > 40% remains uncertain and
several trials are ongoing to determine the best
option [1, 2].
In patients with diabetes, glycaemic control with
a haemoglobin A1c goal < 7% should be encouraged, because it has been associated with a reduction in the risk of incident MI [46] or non-fatal MI.

Cardiac rehabilitation
Patients, and family members, should be educated and actively involved for lifestyle changes
and risk factor management (Table II) [1, 2, 16,
59, 65, 67]. Counselling should start during hospitalization and continue at discharge and during
follow-up [68]. Strategies to encourage healthy
lifestyle changes and adherence to secondary prevention, such as attendance at a cardiac rehabilitation programme and joining a support group,
should be offered [2, 4, 68, 69]. In the French FASTMI registry, prescriptions for cardiac rehabilitation
after acute MI were associated with improved
5-year survival rates, but were only offered to 22%
of patients, indicating considerable room for improvement [68].
Regular attendance at cardiac rehabilitation
is highly recommended, but depends upon the
availability of dedicated centres and sufficient re-

sources. Later sessions can be prescribed by cardiologists every 6 months if appropriate. Patients at
the highest risk (e.g. those with LVEF ≤ 40%) and
young patients who are most likely to return to active and/or professional life should be prioritized.

Leisure-time physical activity and
competitive sports
In the ESC guidelines [69], suitable physical
activity is encouraged in patients with coronary
artery disease (CAD). Patients with higher cardiovascular risk profiles are not eligible for competitive sports but can participate in an individually
designed physical activity, whereas those at lower risk are eligible for low or moderate static and
low dynamic sports [69]. The benefits of regular
physical activity outweigh the low risk of initiating
a coronary event during the exercise session, but
patients with CAD should be given instructions on
appropriate activities to minimize risks and maintain a safe level of intensity [69]. Patients who
have undergone PCI should perform an exercise
test before they resume physical activity. After
completion of outpatient cardiac rehabilitation –
usually 4–6 weeks after the index event – patients
who are asymptomatic may resume a programme
of individually tailored physical activity under the
supervision of a qualified physician [69]. There are
also recommendations available concerning the
statin therapy in patients with intensive exercises and athletes in order to avoid SAMS and statin
intolerance [70].
US guidelines on sport in competitive athletes
[70] state that asymptomatic patients with CAD,
without inducible ischaemia or electrical instability, can reasonably participate in all competitive
activities if their resting LVEF is > 50%. For those
with a lower LVEF, it is reasonable to restrict them
to sports with low dynamic and low–moderate
static demands. Patients with clinically manifest
CAD should be prohibited from participating in
competitive sports for ≥3 months after an acute
MI or coronary revascularization procedure.
According to French law (Article L1172-1), sport
can now be ‘prescribed’ in the context of public
health. The objective of the prescription is to provide 3 months of support (from a massage therapist,
occupational therapist, teacher in adapted physical
activity, sports educator or non-graduate trained
volunteer) and follow-up by a teacher in adapted
physical activity, to lead towards autonomous and
long-term activities on the part of the patient.

Smoking cessation
Smoking cessation is absolutely crucial but
remains suboptimal in the EUROASPIRE surveys
[71]. Nicotine-replacement patches, which have
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been shown to be safe in ACS [72], can be recommended to aid stopping smoking and can be
started during hospitalization. Electronic cigarettes (which deliver a nicotine-containing vapour)
are generally perceived as a ‘healthier alternative’
to conventional cigarettes, but no data exist to
demonstrate their comparative safety, their efficacy in reducing tobacco dependence or their potential cardiovascular effects [73–75].

Quality of life
Quality of life is key, with the goal being to be
able to return to normal daily activities. Guidance
for resumption of daily activities must be based
on LVEF, revascularization success, rhythm control and job characteristics (if in employment) [1].
Sexual activity is reasonable 1 week after an uncomplicated MI in asymptomatic patients during
mild to moderate physical activity (IIa C) [68], but
this should be adjusted based on physical ability (threshold ≥ 3 metabolic equivalent of task).
Driving can be restarted in accordance with each
country’s law. In France, patients should be stabilized (about 5 days if LVEF > 50%; otherwise about
4 weeks after the index event for personal driving, 6 weeks for professional drivers, after specific
evaluation) [76–78].
No restrictions are necessary for long-distance
air travel in asymptomatic patients. For patients
with complicated STEMI, travel should be deferred
until the patient’s condition becomes stable [1].
Return to work depends on each patient’s
profile and previous activity. A simple algorithm
[79, 80] represents a useful tool to help physicians. Guidelines encourage a return to work
1–3 months after an ACS, but this obviously depends on the individual.
Discussion: this expert position aims to help
healthcare professionals in daily practice, as transition care and follow up are complex, as underlined by the high rates of ischaemic and bleeding
events reported by several registries. As some gaps
of evidence remain and need further research, our
advice represents a practical guide that should be
adapted to the patient’s characteristics and preferences, as well as regional access to healthcare.

Conclusions
Follow-up after an ACS represents a crucial
challenge, due to the high residual ischaemic risk,
potential bleeding, to fight therapeutic inertia,
and reinforce therapeutic education. Therefore,
optimal management should be personalised,
reactive and adaptive to clinical situations (recurrent ACS, bleeding events, surgical procedures).
The paternalistic model is no longer valid and
should be replaced by a shared decision-making
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approach. Follow-up is based on a patient-centred
approach, involvement of the patient and family
members and collaboration between health professionals to optimize long-term management.
Checkpoints seem crucial during the first month,
at 3 or 6 months (to shorten the DAPT), and then
at 12 months. The 1-month visit makes it possible
to manage nuisance bleeding, to explain the benefits of treatments, to titrate lipid-lowering treatments if needed, and to repeat educative key messages to patients in order to maintain long-term
adherence and compliance. The 3-and/or 6-month
visit also allows further optimization of lipid-lowering therapy (if necessary) and a risk–benefit
evaluation of DAPT in frail patients, in which it can
be replaced by SAPT. The 1-year evaluation by the
cardiologist aims to identify the minority of patients who may benefit from prolonged DAPT or
a combination of SAPT with low-dose rivaroxaban.
Patients with multivessel coronary disease and/or
polyvascular disease and/or persistent non-controlled risk factors (smoking, diabetes, dyslipidaemia) with a low bleeding risk seem the best candidates. There is no perfect risk score, but the DAPT
score may help to the decision. In the near future,
cognitive computing may become an effective
tool to improve and refine the current scores, and
should be used at the point of care, tailored to individual patient characteristics. Long-term care by
cardiologists improves patient adherence to secondary prevention strategies and lifestyle changes. Healthcare providers must be focused on the
patient’s individual profile and personal level of
risk, and should adapt the strategy every time it is
required. Ongoing trials and registries will provide
further information on the best approach for frail
patients and/or in complex situations.
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